French radiology artificial intelligence (AI) software developer Gleamer has received 7.5 million euros from a series A financing round.
The funds will be used to boost the market launch of its BoneView AI software for detecting traumatic injuries on radiographs, as well as to obtain U.S. Food and Drug Administration (FDA) clearance, according to Gleamer. The vendor said it would also use the investment to continue developing its AI technology in other areas of radiology.
The investment round was led by XAnge, alongside new investors MACSF, Majycc eSanté Invest, and Crista Galli Ventures. Previous investors Elaia and the state-run fund Ambition Amorçage Angels (F3A) also participated, along with 37 radiologists, Gleamer said.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnieeurope.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
